2012

   March 27 - The company was officially established and registered with the Fujian Provincial Administration for Industry and Commerce.    

2013

  May 8, Officially relocated to and commenced operations at the new site in Jinshan Development Zone, Fuzhou.

2014

    November 10 - The clinical trial application for the Class III chemical drug "Azilsartan Tablets" was officially submitted to the National Medical Products Administration (NMPA) for approval.

2015

     February 25 - The clinical trial application for the Class III chemical drug "Sofosbuvir Tablets" was officially submitted to NMPA  for approval.

2016

    March 17 -  "Azishadan Tablets" received the Clinical Trial Approval (CTA) from NMPA.

    May 12 - "Sofibvir Tablets"  received the Clinical Trial Approval (CTA) from NMPA.

    December 30 - The company was nominated the "National High-Tech Enterprise".

2017

    March 29 - The company was recognized as a “Fujian Science and Technology Enterprise”.

    June 29 - The company was recognized as a"Fujian Provincial Innovative R&D Institution".

2020

     June 17 -  "Mosapride Citrate Tablets" was approved for marketing by the NMPA (Approval Number: National Drug Approval No. H20203264).

     August 4 - The company was granted the first Drug manufacturing License under the Marketing Authorization Holder (MAH) system by the Fujian Provincial Drug Administration.

     December 17 - Class I chemical drug C019199 initiated its Phase I clinical trial at Beijing Cancer Hospital.

2021

    January 6 - The "Haixi Pharma R&D and Transformation Center" was inaugurated by the Cangshan District People's Government.

    February 3 - "Mosapride Citrate Tablets" participated in the 4th round of national centralized drug procurement and won the bid.

    March 16 -  "Sinacaside Hydrochloride Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213175).

    March 23 - "Escitalopram oxalate Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213193).

    June 23- "Sinacaside Hydrochloride Tablets" participated in the 5th round of national centralized drug procurement and won the bid.

    October 11- "Celecoxib Capsules" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20213779).

    December 15 - The company was once again recognized as a "National High-Tech Enterprise".

2022

    January 30- "Amlodipine Atorvastatin Calcium Tablets" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20223037).

    April 19 - "Valsartan Amlodipine Tablets (I)" was approved for marketing by NMPA (Drug Approval Number: National Drug Approval No. H20223239).

    June 28 - "Valsartan tablets" was approved for marketing by NMPA (drug approval number: National Drug Approval No. H20223427 (40mg)/H20223428 (80mg)).

    June 29 - A wholly-owned subsidiary, "HaixiPharma Manufacturing (Fuzhou) Co., Ltd." was registered and established in Changle.

    August 19 - The company was awarded the “First Prize in the Growth Enterprise Category" at the 11th China Innovation and Entrepreneurship Competition (Fujian Division) and the 10th Fujian Innovation and Entrepreneurship Competition.

    November 15 - With the approval of the Fujian Provincial Market Supervision and Administration Bureau, the company was officially renamed as "Fujian Haixi Pharmaceutical Co., Ltd.

2023

    March 29 - "Amlodipine Atorvastatin Calcium Tablets" participated in the8th round of national centralized drug procurement and won the bid.

    June 18 - The groundbreaking ceremony was held for the  "Haixi Pharmaceutical Industrialization Base" construction project in Binhai New City, Changle District.

    October 11 _- Haixi designated as a "Fujian Provincial Drug Evaluation and Monitoring Center Training Base".

    October 27 - "Hydroxychloroquine Sulfate Tablets" weas approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20234411).

    November 28 - "Nimaijiaolin Tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20234574).

    December - Haixi was recognized as the "Most Promising Enterprise of Cangshan District".

2024

    April 24 - "Rabeprazole tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20243604).

    June 28 - "Diclofenac Sodium Enteric coated Tablets" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20244225).

    August 5- "Adenosine Cobaltamine Capsules" was approved for marketing by NMPA (drug approval number: National Medical Products Administration Approval No. H20244639).

    September - Nominated as a "National 'Little Giant' Enterprise".

    November- Recognized as the "2024 Fuzhou Enterprise Technology Center".

    December 1 - “Bisoprolol Amlodipine Tablets” was approved for marketing by NMPA (Drug Approval Number: National Medical Products Administration Approval Letter H20249542).

    December 12 - "Hydroxychloroquine Sulfate Tablets" participated in the 10th  round of national centralized drug procurement and won the bid.December – Once again nominated as a “National High-Tech Enterprise.”

2025年    

    January 3, the official application for listing on the Main Board of the Hong Kong Stock Exchange was submitted.

    April 21, Class 1 chemical drug HX9428 Tablets obtained approval for clinical trials.

    June, the Phase Ⅰ clinical trial of HXP056, a Class 1 chemical drug project, was launched at Beijing Hospital.

   June 17, "Cetirizine Hydrochloride Oral Solution" received approval for marketing from the National Medical Products Administration (NMPA) (Drug Approval Number: National Drug Approval H20254566).

    July 30, "Benidipine Hydrochloride Tablets" obtained marketing approval from the National Medical Products Administration (NMPA) (Drug Approval Number: National Drug Approval H20255076).